Webinar: Targeted Protein Degradation (TPD) – The Hidden Treasure
Über das Live Webinar
| Titel: | “Targeted Protein Degradation (TPD) – The Hidden Treasure” |
| Datum | Uhrzeit | Dauer: | Part 1: May 7, 2024 | 4pm CEST / 7am PDT / 8am EDT | 30 Minuten Part 2: May 14, 2024 | 4pm CEST / 7am PDT / 8am EDT | 30 Minuten |
| Speakers | Dr. Helmut Buschmann (Taros Chemicals), Dr. Anil Argarwal (Taros Chemicals) |
Diese Webinar-Serie (Teil 1 + Teil 2) beschäftigt sich mit den neuesten Fortschritten in der Synthese von gezielten Proteindegradierern und erforscht modernste Techniken und Methoden, die die Zukunft therapeutischer Interventionen prägen.
Führende Experten diskutieren innovative Ansätze in der Gestaltung und Synthese von PROTACs und molekularen Klebstoffen, beleuchten zentrale Herausforderungen im Bereich und präsentieren aktuelle Durchbrüche, die die Behandlung komplexer Krankheiten revolutionieren könnten.
Die Teilnehmer werden Einblicke in die sich entwickelnde Landschaft der gezielten Proteindegradation gewinnen, mit einem Schwerpunkt auf den Synthesestrategien, die klinische Anwendungen und therapeutische Wirksamkeit vorantreiben.
Speaker 1) Dr. Helmut Buschmann – Chief Scientific Advisor
Helmut holds a PhD from the RWTH Aachen, Germany. After positions hold at Grünenthal GmbH (Aachen), Laboratorius Dr. Esteve S.A. (Barcelona) and SAVIRA Pharmaceuticals GmbH (Vienna) he is now Head of Chemistry, Pharmaceutical Development and Patents at AiCuris GmbH (Wuppertal) and managing director of Research, Development & Consultancy GmbH (Vienna). As a result of his research activities more than 15 NCEs within different therapeutic areas have entered the clinical phase (e.g. Rosonabant, Cizorlitine, Dulopetine, Axamadol). Some of them have reached clinical phase III or are marketed (e.g. Tapentadol: Nucynta® Palexia®,the first co-crystal of 2 APIs Tramadol and Celecoxib Seglentis®).
He has authored and co-authored more than 150 scientific and peer reviewed publications, is named as lead inventor in more than 250 patent families and has edited five books in the field of drug discovery and development. In 2014, he was awarded with the IUPAC-Richter Price for the discovery of the pain killer Tapentadol, which is marketed word-wide as Palexia® (Europe) and Nucynta® (US and Canada).
His research interests are drug impurities and the systematic recording of degradation pathways. He authored one of the first publications describing potential root causes for nitrosamine contamination. Since this time he was invited to several national and international congresses and is consulted as an expert in this field by academic institutes, pharmaceutical companies and regulatory authorities.
Speaker 2) Dr. Anil Argarwal – Head of Medicinal Chemistry
Anil is a distinguished medicinal chemist with over 17 years of experience specializing in early drug discovery across various
therapeutic areas including Oncology, Neuroscience, anti-infectives, and metabolic diseases.
A PhD graduate from the University of Leeds, Anil has contributed
significantly to the field, notably as a coinventor of two clinical-stage molecules:
ALK5i – PF 06952229 (Pfizer) and CDK 2,4,6 inhibitor – NUV-422 (Nuvation Bio), both currently in Phase-I trials.
His recent work includes leading over ten drug discovery projects, advancing two clinical candidates, and numerous lead molecules in areas such as oncology and liver disease.
Notably, a molecular glue has been nominated for further development with Anil credited as an inventor. His expertise extends to optimizing lead molecules through structure-activity relationship analysis, greatly enhancing project outcomes and organizational growth.
Any questions before our webinar?
contact us in advance to arrange a personal meeting
Drug Discovery
Custom Synthesis
We support our customers by providing first kg quantities of fine and specialty chemicals, cost reduction of existing syntheses, streamlining chemical processes considering…
